PFENYSEPharmaceutical PreparationsFiscal year ends December 31
PFIZER INC
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026
$29.44−0.14 (-0.47%)
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
PFIZER INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma [Member] | $14.66B | $14.16B | $17.14B | $16.31B | $14.31B | $13.44B | $17.41B | $17.39B | $12.99B | $14.60B | $14.19B | $13.19B | 97.5% | +2.5% |
| Business Innovation Segment [Member] | – | – | – | – | – | – | – | – | – | $275.00M | $382.00M | $302.00M | – | – |
| Pfizer CentreOne [Member] | – | – | – | – | – | – | – | $285.00M | $278.00M | – | – | $293.00M | – | – |
| Pfizer Ignite [Member] | – | – | – | – | – | – | – | $25.00M | $15.00M | – | – | $10.00M | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $11.86B | $11.72B | $14.50B | $13.92B | $11.95B | $11.29B | $15.09B | $15.42B | $10.87B | $12.44B | $12.34B | $11.59B | 78.9% | -0.8% |
| Royalty [Member] | $474.00M | $396.00M | $480.00M | $436.00M | $426.00M | $308.00M | $431.00M | $384.00M | $345.00M | $263.00M | $321.00M | $260.00M | 3.2% | +11.3% |
| Pfizer CentreOne [Member] | $373.00M | $289.00M | $409.00M | $344.00M | $348.00M | $273.00M | $326.00M | $285.00M | $278.00M | $258.00M | – | – | 2.5% | +7.2% |
| Pfizer Ignite [Member] | – | – | $4.00M | $0 | $20.00M | $17.00M | $26.00M | $25.00M | $15.00M | $17.00M | – | – | – | – |
| Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member] | – | – | – | – | – | – | $0 | $442.00M | – | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $8.86B | $8.73B | $9.12B | $10.69B | $8.89B | $8.37B | $9.22B | $12.06B | $7.89B | $9.51B | $4.91B | $8.06B | 58.9% | -0.4% |
| International Developed Markets [Member] | $3.74B | $3.43B | $5.92B | $3.70B | $3.39B | $3.18B | $6.28B | $3.41B | $3.16B | $3.20B | $7.82B | $3.34B | 24.9% | +10.3% |
| International Emerging Markets [Member] | $2.43B | $2.29B | $2.52B | $2.27B | $2.37B | $2.16B | $2.26B | $2.23B | $2.23B | $2.17B | $1.84B | $2.09B | 16.2% | +2.9% |
| Developed Rest of World [Member] | – | – | – | – | – | – | – | – | – | – | $2.91B | $1.07B | – | – |
| Emerging Markets [Member] | – | – | – | – | – | – | – | – | – | – | $2.32B | $2.37B | – | – |
| Developed Europe [Member] | – | – | – | – | – | – | – | – | – | – | $4.43B | $1.98B | – | – |
From the segment and revenue-disaggregation notes of Pfizer's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.